Eleven Biotherapeutics, Inc. (EBIO) was a big mover last session, as its shares rose almost 9% on the day. This led to more shares changing hands than in a normal session. Yesterday’s rally continues the uptrend for the company since Apr 6, as the stock is now up over 28%.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Eleven Biotherapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is Affymetrix Inc. (AFFX) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment